Cushing's Syndrome in Women With Polycystic Ovaries and Hyperandrogenism

P. Gerry Fegan; Derek D. Sandeman; Nils Krone; Deborah Bosman; Peter J. Wood; Paul M. Stewart; Neil A. Hanley

Nat Clin Pract Endocrinol Metab. 2007;3(11):778-783.

Conclusions

The Rotterdam Consensus Statement establishes criteria for the diagnosis of PCOS only when other etiologies have been excluded. The importance of this caveat is illustrated by the presented case and three additional reported cases, in each of which Cushing's syndrome was missed. Recent data obtained by screening individuals with type 2 diabetes suggest that cortisol excess, widely considered a rare endocrinopathy in the form of classical Cushing's syndrome, is in fact more common than supposed. As economic pressures drive health care to be delivered within fewer consultation sessions outside of specialist centers, it is pertinent to emphasize that not all cases of hyperandrogenism or ovarian cysts are related to PCOS and that curable causes, such as Cushing's syndrome, must be excluded by careful history taking, examination and (potentially repeated) investigation.

CLICK HERE for subscription information about this journal.

1 2 3 4 5

Next Section

Acknowledgments

Written consent for publication of Figure 1 was obtained from the patient.

Reprint Address

Correspondence: School of Medicine, University of Southampton, Duthie Building / Mailpoint 808, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, UK; Email: n.a.hanley@soton.ac.uk

Cite this: Cushing's Syndrome in Women With Polycystic Ovaries and Hyperandrogenism - Medscape - Nov 01, 2007.

Table 1. Three Additional Women With Very Similar Clinical Features Eventually Diagnosed With Cushing's Syndrome
Features	Patients
Features	The Case (A)	Case B	Case C	Case D
Age at diagnosis of Cushing's syndrome; gap since first investigated	41 years; 7 years	24 years; 3 months	35 years; 1 year	25 years; 12 years
Diagnosis	Right adrenal adenoma	Corticotroph adenoma	Corticotroph adenoma	Corticotroph adenoma
Pelvic ultrasound or laparoscopy result	Polycystic ovaries	Polycystic ovaries	Polycystic ovaries	Polycystic ovaries
Clinical features initially attributed to PCOS	Hirsutism, subfertility, greasy skin and acne	Hirsutism, secondary amenorrhea, weight gain	Subfertility, weight gain	Obesity, weight gain, primary amenorrhea
Serum total testosterone	2.6 nmol/l (75 ng/dl)	4.6 nmol/l (133 ng/dl)	3.2 nmol/l (92 ng/dl)	4.5 nmol/l (130 ng/dl)
Screening test confirming Cushing's syndrome	Overnight LDDST Three 24-h UFC collections Bedtime salivary cortisol measurement	Overnight LDDST Three 24-h UFC collections	Overnight LDDST Three 24-h UFC collections Bedtime salivary cortisol measurement	Overnight LDDST Three 24-h UFC collections 0900 h and 2400 h cortisol measurement
Clinical features that distinguished Cushing's syndrome from PCOS (see Table 2 )	Facial plethora, rounded facies, violaceous abdominal striae	Facial plethora	None	Short stature,^a depression
Biochemical investigation against a diagnosis of PCOS	Low estradiol (47 pmol/l [13 pg/ml])	None	None	Low LH (1.1 IU/l) and low estradiol
Hypertension	Yes	No	Yes	No
Diabetes or impaired glucose tolerance	No	No	Yes	No
Hypertension	Yes	No	Yes	No
Diabetes or impaired glucose tolerance	No	No	Yes	No
Final curative treatment	Laparoscopic right adrenalectomy	Transsphenoidal surgery	Transsphenoidal surgery	Transsphenoidal surgery

^aShort stature with obesity is a particularly useful feature pointing towards Cushing's syndrome in childhood or adolescence.
Abbreviations: LDDST = low dose dexamethasone suppression test; LH = luteinizing hormone; PCOS = polycystic ovarian syndrome; UFC = urinary free cortisol.

Table 1. Three Additional Women With Very Similar Clinical Features Eventually Diagnosed With Cushing's Syndrome
Features	Patients
Features	The Case (A)	Case B	Case C	Case D
Age at diagnosis of Cushing's syndrome; gap since first investigated	41 years; 7 years	24 years; 3 months	35 years; 1 year	25 years; 12 years
Diagnosis	Right adrenal adenoma	Corticotroph adenoma	Corticotroph adenoma	Corticotroph adenoma
Pelvic ultrasound or laparoscopy result	Polycystic ovaries	Polycystic ovaries	Polycystic ovaries	Polycystic ovaries
Clinical features initially attributed to PCOS	Hirsutism, subfertility, greasy skin and acne	Hirsutism, secondary amenorrhea, weight gain	Subfertility, weight gain	Obesity, weight gain, primary amenorrhea
Serum total testosterone	2.6 nmol/l (75 ng/dl)	4.6 nmol/l (133 ng/dl)	3.2 nmol/l (92 ng/dl)	4.5 nmol/l (130 ng/dl)
Screening test confirming Cushing's syndrome	Overnight LDDST Three 24-h UFC collections Bedtime salivary cortisol measurement	Overnight LDDST Three 24-h UFC collections	Overnight LDDST Three 24-h UFC collections Bedtime salivary cortisol measurement	Overnight LDDST Three 24-h UFC collections 0900 h and 2400 h cortisol measurement
Clinical features that distinguished Cushing's syndrome from PCOS (see Table 2 )	Facial plethora, rounded facies, violaceous abdominal striae	Facial plethora	None	Short stature,^a depression
Biochemical investigation against a diagnosis of PCOS	Low estradiol (47 pmol/l [13 pg/ml])	None	None	Low LH (1.1 IU/l) and low estradiol
Hypertension	Yes	No	Yes	No
Diabetes or impaired glucose tolerance	No	No	Yes	No
Hypertension	Yes	No	Yes	No
Diabetes or impaired glucose tolerance	No	No	Yes	No
Final curative treatment	Laparoscopic right adrenalectomy	Transsphenoidal surgery	Transsphenoidal surgery	Transsphenoidal surgery

Table 2. Causes of Hyperandrogenism, Other Than Polycystic Ovarian Syndrome, Which Merit Consideration, Especially if Irregularity of the Menstrual Cycle Does not Date Back to Menarche
'Non-PCOS' causes of hyperandrogenism	Distinguishing clinical features	Screening tests to consider
Cushing's syndrome	Facial plethora, rounded facies, violaceous striae, thin skin, bruising and proximal muscle weakness In younger patients: growth arrest, primary amenorrhea	See Table 3
Late onset congenital adrenal hyperplasia	Positive family history	Serum 17α-hydroxyprogesterone
Drugs (e.g. anabolic steroids, androgenic progesterones)	Onset timed with drug-taking	Gas chromatography or liquid chromatography plus mass spectrometry
Androgen-secreting adrenocortical or ovarian tumor	Progressive virilization	DHEAS (adrenocortical tumor) Serum total testosterone: androgen-secreting tumors are unlikely if levels are below 4 nmol/l (115 ng/dl) and become increasingly probable with higher values; PCOS is rarely associated with values higher than 7 nmol/l^a (202 ng/dl)
Acromegaly	Bony and soft tissue overgrowth	Oral glucose tolerance test Serum IGF-I

^aFor detailed review, see Kaltsas GA et al.^[7]
Abbreviations: DHEAS = dehydroepiandrosterone sulfate; IGF-I = insulin-like growth factor I; PCOS = polycystic ovarian syndrome.

Table 1. Three Additional Women With Very Similar Clinical Features Eventually Diagnosed With Cushing's Syndrome
Features	Patients
Features	The Case (A)	Case B	Case C	Case D
Age at diagnosis of Cushing's syndrome; gap since first investigated	41 years; 7 years	24 years; 3 months	35 years; 1 year	25 years; 12 years
Diagnosis	Right adrenal adenoma	Corticotroph adenoma	Corticotroph adenoma	Corticotroph adenoma
Pelvic ultrasound or laparoscopy result	Polycystic ovaries	Polycystic ovaries	Polycystic ovaries	Polycystic ovaries
Clinical features initially attributed to PCOS	Hirsutism, subfertility, greasy skin and acne	Hirsutism, secondary amenorrhea, weight gain	Subfertility, weight gain	Obesity, weight gain, primary amenorrhea
Serum total testosterone	2.6 nmol/l (75 ng/dl)	4.6 nmol/l (133 ng/dl)	3.2 nmol/l (92 ng/dl)	4.5 nmol/l (130 ng/dl)
Screening test confirming Cushing's syndrome	Overnight LDDST Three 24-h UFC collections Bedtime salivary cortisol measurement	Overnight LDDST Three 24-h UFC collections	Overnight LDDST Three 24-h UFC collections Bedtime salivary cortisol measurement	Overnight LDDST Three 24-h UFC collections 0900 h and 2400 h cortisol measurement
Clinical features that distinguished Cushing's syndrome from PCOS (see Table 2 )	Facial plethora, rounded facies, violaceous abdominal striae	Facial plethora	None	Short stature,^a depression
Biochemical investigation against a diagnosis of PCOS	Low estradiol (47 pmol/l [13 pg/ml])	None	None	Low LH (1.1 IU/l) and low estradiol
Hypertension	Yes	No	Yes	No
Diabetes or impaired glucose tolerance	No	No	Yes	No
Hypertension	Yes	No	Yes	No
Diabetes or impaired glucose tolerance	No	No	Yes	No
Final curative treatment	Laparoscopic right adrenalectomy	Transsphenoidal surgery	Transsphenoidal surgery	Transsphenoidal surgery

Table 3. Screening Tests for Cushing's syndrome
Perturbation to normal physiology	Screening test for Cushing's syndrome^a	Potential use during 'work-up'
At least partial autonomy of cortisol production (either direct from the adrenal cortex or secondary to adrenocorticotropic hormone secretion)	Failure to suppress cortisol levels below 50 nmol/l after low dose dexamethasone (0.5 mg every 6 h for eight doses ending at 0300 h, or 1 mg at 2300 h with serum cortisol measured the following day at 0800 h to 0900 h)	A useful out-patient first-line investigation
Loss of diurnal rhythm of cortisol production	High midnight or bedtime cortisol (serum or salivary)	Salivary assays are practical, because multiple samples can be posted to the laboratory over the course of a few days. Useful if backed up by a robust normal range
Excess cortisol production leading to increased free cortisol excretion	Increased 24-h urinary free cortisol	Useful investigation, but patients can find it inconvenient or difficult; commonly performed three times

^aPhysicians should retain a high index of suspicion and be willing to repeat screening tests. Salivary cortisol measurements are particularly useful to investigate cyclical Cushing's syndrome.

Table 3. Screening Tests for Cushing's syndrome
Perturbation to normal physiology	Screening test for Cushing's syndrome^a	Potential use during 'work-up'
At least partial autonomy of cortisol production (either direct from the adrenal cortex or secondary to adrenocorticotropic hormone secretion)	Failure to suppress cortisol levels below 50 nmol/l after low dose dexamethasone (0.5 mg every 6 h for eight doses ending at 0300 h, or 1 mg at 2300 h with serum cortisol measured the following day at 0800 h to 0900 h)	A useful out-patient first-line investigation
Loss of diurnal rhythm of cortisol production	High midnight or bedtime cortisol (serum or salivary)	Salivary assays are practical, because multiple samples can be posted to the laboratory over the course of a few days. Useful if backed up by a robust normal range
Excess cortisol production leading to increased free cortisol excretion	Increased 24-h urinary free cortisol	Useful investigation, but patients can find it inconvenient or difficult; commonly performed three times

^aPhysicians should retain a high index of suspicion and be willing to repeat screening tests. Salivary cortisol measurements are particularly useful to investigate cyclical Cushing's syndrome.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

Cushing's Syndrome in Women With Polycystic Ovaries and Hyperandrogenism

Conclusions

Tables

Tables

Tables

Tables

Tables

Tables

References

Authors and Disclosures

Authors and Disclosures

Comments

Email This

Feedback